TEVA Q3 2024 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.3B+12.5% YoY

Gross Profit

$2.1B49.6% margin

Operating Income

-$51M-1.2% margin

Net Income

-$437M-10.1% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

$693M

Free Cash Flow

$545M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$41.8B

Total Liabilities

$35.4B

Stockholders' Equity

$6.1B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$3.9B	+12.5%
Gross Profit	$2.1B	$1.9B	+16.0%
Operating Income	-$51M	$344M	-114.8%
Net Income	-$437M	$69M	-733.3%

Revenue Segments

Product

$3.8B88%

Distribution Service

$390M9%

Product and Service, Other

$102M2%

License

$45M1%

Geographic Segments

North America Segment

$2.2B54%

Europe Segment

$1.3B31%

International Markets

$613M15%